OTC shake-up likely as regulators mull centralised clearing

US legislators are pressing for reforms that will lead to a big shake-up in how over-the-counter derivatives are bought and sold. The question is how this will affect the structured notes market. John Ferry reports

The outlook is uncertain for OTC derivatives

With President Barack Obama’s healthcare bill finally passed, financial regulatory reform in the US is likely to move back up the political agenda in coming months. A major part of the reform effort focuses on over-the-counter derivatives, with a number of bills being debated by Congress that aim to formalise oversight and move a big chunk of the market onto exchanges. The plethora of bills that have come out make it difficult to foresee what the likely impact of final legislation will be, but

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact info@risk.net or view our subscription options here: http://subscriptions.risk.net/subscribe

You are currently unable to copy this content. Please contact info@risk.net to find out more.

Sorry, our subscription options are not loading right now

Please try again later. Get in touch with our customer services team if this issue persists.

New to Risk.net? View our subscription options

Most read articles loading...

You need to sign in to use this feature. If you don’t have a Risk.net account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here